Brief: Avacta Group Announces FDA Agreement On Pivotal Trial Design For Ava6000
Today 07:49
BRIEF-Avacta Group Announces FDA Agreement On Pivotal Trial Design For Ava6000 June 25 (Reuters) - Avacta Group PLC AVCT.L:
FDA AGREEMENT ON PIVOTAL TRIAL DESIGN FOR AVA6000
SINGLE PIVOTAL TRIAL WITH PROGRESSION-FREE SURVIVAL AS PRIMARY ENDPOINT FOR FULL APPROVAL
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Avacta
See all newsBrief: Avacta Group Reports Platform-Validating Data With Faridoxorubicin
Brief: Avacta Group Announces FDA Agreement On Pivotal Trial Design For Ava6000
FDA Agreement on Pivotal Trial Design for AVA6000
Platform-Validating Data with Faridoxorubicin
Brief: Avacta Therapeutics Appoints Richard Hughes As Non-Executive Chairman